[go: up one dir, main page]

AR026356A1 - Metodo para tratar la diabetes - Google Patents

Metodo para tratar la diabetes

Info

Publication number
AR026356A1
AR026356A1 ARP000105805A ARP000105805A AR026356A1 AR 026356 A1 AR026356 A1 AR 026356A1 AR P000105805 A ARP000105805 A AR P000105805A AR P000105805 A ARP000105805 A AR P000105805A AR 026356 A1 AR026356 A1 AR 026356A1
Authority
AR
Argentina
Prior art keywords
diabetes
treat diabetes
post
treatment
prandial
Prior art date
Application number
ARP000105805A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/432,465 external-priority patent/US6586438B2/en
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR026356A1 publication Critical patent/AR026356A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/64Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporciona un método para el tratamiento de la diabetes del Tipo 2 empleando una combinacion de metformina y gliburida. También se proporciona unmétodo para el tratamiento de diabetes en pacientes sin experiencia en el fármaco empleando la formul acion anterior para reducir la resistencia a la insulinay/o la excursion de la glucosa post-prandial y/o la hemoglobina 1Ac, y/o el incremento de la insulina post-prandial, tratando así la diabetes.
ARP000105805A 1999-11-03 2000-11-03 Metodo para tratar la diabetes AR026356A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/432,465 US6586438B2 (en) 1999-11-03 1999-11-03 Antidiabetic formulation and method
US09/460,920 US7598262B2 (en) 1999-11-03 1999-12-14 Method for treating diabetes

Publications (1)

Publication Number Publication Date
AR026356A1 true AR026356A1 (es) 2003-02-05

Family

ID=27029501

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000105805A AR026356A1 (es) 1999-11-03 2000-11-03 Metodo para tratar la diabetes

Country Status (23)

Country Link
EP (1) EP1229918B1 (es)
JP (1) JP5183844B2 (es)
KR (1) KR20070089259A (es)
CN (1) CN1450902A (es)
AR (1) AR026356A1 (es)
AT (1) ATE390140T1 (es)
AU (1) AU780106B2 (es)
BR (1) BR0015294A (es)
CA (1) CA2389928C (es)
EE (1) EE05260B1 (es)
HU (1) HU229352B1 (es)
IL (1) IL149139A0 (es)
LT (1) LT5058B (es)
LV (1) LV12910B (es)
MX (1) MXPA02004282A (es)
NO (1) NO330026B1 (es)
NZ (1) NZ518278A (es)
PL (1) PL199278B1 (es)
RU (1) RU2275915C2 (es)
SK (1) SK287810B6 (es)
TW (1) TWI280125B (es)
UY (1) UY26424A1 (es)
WO (1) WO2001032157A2 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563774B2 (en) 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
FR2816840B1 (fr) 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
FR2825023B1 (fr) * 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
WO2003011273A1 (en) * 2001-07-31 2003-02-13 The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Metformin in the treatment of hyperglycemic conditions
EP1492511B3 (fr) 2002-04-09 2012-05-02 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
AU2002356419A1 (en) 2002-06-17 2003-12-31 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
US20080090859A1 (en) * 2003-10-30 2008-04-17 Tioga Pharmaceuticals, Inc. Use of Selective Opiate Receptor Modulators In the Treatment Of Neuropathy
KR101329369B1 (ko) * 2003-12-19 2013-11-14 오메가 바이오 파마(아이.피.3) 리미티드 당뇨 치료용 조성물 및 방법
CA2565250C (en) * 2004-05-03 2013-11-12 Omega Bio-Pharma (I.P.3) Limited Cysteamines for treating complications of hypercholesterolemia and diabetes
UA98799C2 (ru) 2007-07-19 2012-06-25 Такеда Фармасьютикал Компани Лимитед Твердый препарат, включающий алоглиптин и гидрохлорид метформина
SI2200606T1 (sl) 2007-09-10 2017-12-29 Janssen Pharmaceutica N.V. Postopek za pripravo spojin, uporabnih kot inhibitorjev SGLT
RU2372911C1 (ru) * 2008-03-12 2009-11-20 Николай Евгеньевич Староверов Полиморфная аналоговая терапия
US9056850B2 (en) 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
CN103736082A (zh) 2008-10-17 2014-04-23 赛诺菲-安万特德国有限公司 胰岛素和glp-1激动剂的组合
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
AU2010317995B2 (en) 2009-11-13 2014-04-17 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine
CN102711804B (zh) 2009-11-13 2015-09-16 赛诺菲-安万特德国有限公司 包含glp-1激动剂和甲硫氨酸的药物组合物
ES2596291T3 (es) 2010-05-11 2017-01-05 Janssen Pharmaceutica, N.V. Formulaciones farmacéuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienilmetilbenceno como inhibidores de sglt
PT2611458T (pt) 2010-08-30 2016-12-16 Sanofi Aventis Deutschland Utilização de ave0010 para o fabrico de um medicamento para o tratamento da diabetes mellitus tipo 2
TW201236692A (en) * 2011-02-02 2012-09-16 Sanofi Aventis Deutschland Prevention of hypoglycaemia in diabetes mellitus type 2 patients
US20120277147A1 (en) * 2011-03-29 2012-11-01 Sanofi-Aventis Deutschland Gmbh Prevention of hypoglycaemia in diabetes mellitus type 2 patients
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
KR102578030B1 (ko) 2014-12-12 2023-09-14 사노피-아벤티스 도이칠란트 게엠베하 인슐린 글라진/릭시세나티드 고정비 제형
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患之治療
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
CN110804017A (zh) * 2019-10-31 2020-02-18 天津大学 磺酰脲化合物与二甲双胍成盐、制备方法和应用
CN113143940A (zh) * 2020-12-30 2021-07-23 成都恒瑞制药有限公司 一种抗糖尿病药物组合物的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
DE3833439A1 (de) * 1988-10-01 1991-09-12 Hoechst Ag Verfahren zur mikronisierung von glibenclamid
DK36392D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IT1276130B1 (it) * 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
CA2294582C (en) 1997-06-18 2008-02-12 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione and metformin
CA2312990C (en) * 1997-12-08 2008-04-29 Bristol-Myers Squibb Company Novel salts of metformin and method
ATE250418T1 (de) * 1998-07-15 2003-10-15 Merck Sante Sas Tabletten enthaltend eine kombination von glibenclamid und metformin
EP2620443A1 (en) 2012-01-25 2013-07-31 Galecto Biotech AB Novel galactoside inhibitors of galectins

Also Published As

Publication number Publication date
AU780106B2 (en) 2005-03-03
NZ518278A (en) 2004-10-29
ATE390140T1 (de) 2008-04-15
HUP0300218A3 (en) 2006-02-28
EP1229918A2 (en) 2002-08-14
CN1450902A (zh) 2003-10-22
MXPA02004282A (es) 2003-02-17
JP5183844B2 (ja) 2013-04-17
CA2389928C (en) 2010-03-23
EE05260B1 (et) 2010-02-15
EP1229918B1 (en) 2008-03-26
LT2002063A (en) 2003-06-25
NO20022087L (no) 2002-06-24
AU1082601A (en) 2001-05-14
LV12910B (en) 2003-05-20
RU2275915C2 (ru) 2006-05-10
SK287810B6 (sk) 2011-10-04
JP2003519621A (ja) 2003-06-24
EE200200242A (et) 2003-12-15
NO20022087D0 (no) 2002-05-02
WO2001032157A2 (en) 2001-05-10
HUP0300218A2 (hu) 2003-06-28
WO2001032157A3 (en) 2002-01-24
RU2002114820A (ru) 2004-03-10
NO330026B1 (no) 2011-02-07
SK5002002A3 (en) 2004-05-04
LT5058B (lt) 2003-09-25
IL149139A0 (en) 2002-11-10
PL199278B1 (pl) 2008-09-30
BR0015294A (pt) 2003-07-15
UY26424A1 (es) 2001-05-31
KR20070089259A (ko) 2007-08-30
PL364885A1 (en) 2004-12-27
HU229352B1 (en) 2013-11-28
TWI280125B (en) 2007-05-01
CA2389928A1 (en) 2001-05-10

Similar Documents

Publication Publication Date Title
AR026356A1 (es) Metodo para tratar la diabetes
Hamada et al. Electrical stimulation of human lower extremities enhances energy consumption, carbohydrate oxidation, and whole body glucose uptake
TNSN00206A1 (en) Method for treating diabetes
MY155270A (en) Use of glp-1 or analogs in treatment of stroke
BR0109336A (pt) Medicamento para a prevenção, melhora e/ou tratamento de uma complicação diabética, droga medicinal adequada ou utilizável como o mesmo, método para prevenir, melhorar e/ou tratar a complicação diabética, e a neuropatia, e, usos de um agente redutor do açúcar no sangue pós-prandial e pelo menos um agente selecionado de um agente anti-hipertensivo, um agente vasodilatador e um agente anti-hiperlipidêmico
FI3524261T3 (fi) Exendin käytettäväksi diabeteksen hoidossa ja ruumiin painon vähentämiseksi
DE60036367D1 (de) Synergitische verwendung von thiazolidinedionen und glucagon-ähnlichem peptid-1 und dessen agonisten für die behandlung von nicht-insulin-abhängigen diabetes
PT1173178E (pt) Composicao compreendendo apomorfina e sildenafil e utilizacao da mesma para o tratamento da disfuncao erectil
DE60334147D1 (de) Plazentäre alkalische phosphatase zur diabeteskontrolle
Tschopp et al. Local injection therapy in 107 patients with myofascial pain syndrome of the head and neck
DE50110262D1 (de) Verwendung von bradycardica bei der behandlung von mit hypertrophie einhergehenden myocarderkrankungen und neue arzneimittelkombinationen
DK30092A (da) Fremgangsmaade og midler til ikke-invasiv aedosis-til-virkningae administration af lipofile laegemidler
BR0104586A (pt) Método para tratamento de neurodegeneração
ES2182840T3 (es) Factor xiii para el tratamiento de heridas de la piel.
RU2004103531A (ru) Фармацевтическая композиция для перорального применения, содержащая одновременно метформин и гликлазид
RU2002120168A (ru) Способ лечения ишемических заболеваний глаз
DE602004025040D1 (de) Den blutzuckerspiegel bei diabetes mellitus regulierendes tetrapeptid
RU2002109173A (ru) Способ лечения дистрофических заболеваний сетчатой оболочки глаза
SE9101341D0 (sv) New medicinal use
RU2006142622A (ru) Способ лечения острого инфаркта миокарда
Chen et al. Hypoglycemic Effect and Mechanism of ICK Pattern Peptides
MX2021014997A (es) Agente de vanadio y metformina como principio activo para el tratamiento de padecimientos relacionados con la resistencia a la insulina.
RU2001103672A (ru) Способ лечения больных артериальной гипертензией
Narbutt et al. Local photochemotherapy in treatment of necrobiosis lipoidica
US20030198686A1 (en) Chinese medicinal composition

Legal Events

Date Code Title Description
FB Suspension of granting procedure